Sterile Product Recalls Reflect FDA Inspection Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug recalls for 2003 included a significant number of cases involving microbial contamination of injectable products. Counterfeit versions of products resulted in four of the 181 recalls during the year.
You may also be interested in...
Pharmacy Compounding Accreditation Board Set Up By Trade Groups
The initial focus will be on sterile compounding in the community practice setting. Accreditation of sites could begin by the end of the year.
FDA Creates CMC Pilots To Put Quality Assessment Principles Into Practice
NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.